SG47639A1 - Method of treating hyperproliferative vascular disease - Google Patents

Method of treating hyperproliferative vascular disease

Info

Publication number
SG47639A1
SG47639A1 SG1996003304A SG1996003304A SG47639A1 SG 47639 A1 SG47639 A1 SG 47639A1 SG 1996003304 A SG1996003304 A SG 1996003304A SG 1996003304 A SG1996003304 A SG 1996003304A SG 47639 A1 SG47639 A1 SG 47639A1
Authority
SG
Singapore
Prior art keywords
vascular disease
treating hyperproliferative
hyperproliferative vascular
treating
hyperpoliferative
Prior art date
Application number
SG1996003304A
Other languages
English (en)
Inventor
Clare Robert Grefory
Randell Ellis Morris
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of SG47639A1 publication Critical patent/SG47639A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG1996003304A 1992-01-09 1993-01-06 Method of treating hyperproliferative vascular disease SG47639A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81931492A 1992-01-09 1992-01-09

Publications (1)

Publication Number Publication Date
SG47639A1 true SG47639A1 (en) 1998-04-17

Family

ID=25227805

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996003304A SG47639A1 (en) 1992-01-09 1993-01-06 Method of treating hyperproliferative vascular disease

Country Status (15)

Country Link
EP (1) EP0551182B1 (de)
JP (1) JP2644955B2 (de)
KR (1) KR100276142B1 (de)
AT (1) ATE194493T1 (de)
AU (1) AU665041B2 (de)
CA (1) CA2086642C (de)
DE (1) DE69328981T2 (de)
DK (1) DK0551182T3 (de)
ES (1) ES2147740T3 (de)
GR (1) GR3034479T3 (de)
HK (1) HK1010332A1 (de)
LV (1) LV12603B (de)
NZ (1) NZ245630A (de)
PT (1) PT551182E (de)
SG (1) SG47639A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
NZ533467A (en) 1993-07-19 2006-02-24 Angiotech Pharm Inc Anti-angiogenic compositions and methods of use
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
WO1996041807A1 (en) 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
KR100616020B1 (ko) * 1996-03-27 2007-01-31 노파르티스 아게 맥관장애및이종이식술에서의라파마이신유도체의용도
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) † 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en) 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
EP1498084B1 (de) 2000-10-16 2014-06-18 Innovational Holdings, LLC Expandierbare medizinische Vorrichtung zum Zuführen eines Heilmittels
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ATE538820T1 (de) 2003-02-21 2012-01-15 Sorin Biomedica Cardio Srl Verfahren zur herstellung eines stents und entsprechender stent
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US8192483B2 (en) 2005-10-06 2012-06-05 Kaneka Corporation Stent to be placed in the living body
PL2386322T3 (pl) 2006-07-03 2018-06-29 Hemoteq Ag Wytwarzanie, sposób i zastosowanie produktów leczniczych uwalniających środki do trwałego otwierania naczyń krwionośnych
CN101972492B (zh) 2007-01-21 2014-12-10 汉莫堤克股份有限公司 治疗体通道狭窄和预防危险的再狭窄的医学产品
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8921642B2 (en) 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP3064230B1 (de) 2009-07-10 2019-04-10 Boston Scientific Scimed, Inc. Verwendung von nanokristallen für einen wirkstofffreisetzungsballon
JP5933434B2 (ja) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 薬剤送達バルーンの製造方法
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
JP6278332B2 (ja) 2013-04-22 2018-02-14 スズキ株式会社 変速機の制御装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
AU3107993A (en) 1993-07-15
ATE194493T1 (de) 2000-07-15
EP0551182B1 (de) 2000-07-12
DE69328981T2 (de) 2000-11-16
GR3034479T3 (en) 2000-12-29
LV12603B (en) 2001-04-20
ES2147740T3 (es) 2000-10-01
CA2086642C (en) 2004-06-15
DE69328981D1 (de) 2000-08-17
DK0551182T3 (da) 2000-10-09
HK1010332A1 (en) 1999-06-17
PT551182E (pt) 2000-12-29
LV12603A (en) 2001-01-20
JPH069390A (ja) 1994-01-18
CA2086642A1 (en) 1993-07-10
JP2644955B2 (ja) 1997-08-25
AU665041B2 (en) 1995-12-14
KR100276142B1 (ko) 2001-02-01
NZ245630A (en) 1997-07-27
KR930016102A (ko) 1993-08-26
EP0551182A1 (de) 1993-07-14

Similar Documents

Publication Publication Date Title
SG47639A1 (en) Method of treating hyperproliferative vascular disease
AU1791895A (en) Method of preventing hyperproliferative vascular disease
CA2094858A1 (en) Method of treating hyperproliferative vascular disease
GR3027610T3 (en) Rapamycin for the treatment of Crohn's disease, ulcerative colitis or ulcerative proctitis
AU696851B2 (en) Method of treating hyperproliferative vascular disease
NL300174I1 (nl) Toepassing van venlafaxine of een aryloxypropaanamineverbinding voor de bereiding van een geneesmiddel voor de behandeling van incontinentie.
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
GR3020310T3 (en) 29-Demethoxyrapamycin for inducing immunosuppression
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
LTIP1423A (en) Device for treatment of gullet stricture